The device was used for treatment.Two 6f safesheath ii introducer sheaths were returned from the customer without dilator.Both sheaths were already peeled apart by the customer upon receipt of the product.There were no other accessories.Traces of blood were found on and inside of both sheaths.The sheaths were reported from 2 different lots.Both sheaths were received in the same bag, so it is not possible to differentiate one lot from the other.On review of both the sheaths, the scorelines of the peeled sheaths were found to be normal and smooth.It was confirmed that the hemostatic valve in sheath split along half of its diameter and could not split apart completely.Break force test data was reviewed and showed that all data was within tolerance.Returned devices analysis reveals that hemostatic valves were torn and fatigued and the pegs of the introducers looked good.The exact root cause of seal not able to split remains inconclusive.The probable cause of this issue could be if the valve had not been seated properly on the pegs then the valve may slip out during peeling process.The event will be re-evaluated if additional information becomes available.Oscor will continue to monitor this event type.The device history records were reviewed to confirm that the device passed all applicable in-process and final inspections.Per procedure (adelante-s introducer sheath in process and final inspection).Qa performs inspection as per sampling plan ansi z 1.4, special level 4, aql 0.40 reduced.Break and peel test: using samples from fit check, manually break the sheath and hub and verify that the seal splits easily without extreme elongation.Also verify that the split cap and seal remain secure and do not break free or loosen from the sheath hub.Manually peel the sheath and verify the sheath peels easily along the sheath body and tip.Per ifu sharply snap the tabs of valve housing in a plane perpendicular to the long axis of the sheath to split the valve and peel sheath apart while withdrawing from the vessel.No further follow-up is required.Based on the investigation, a capa is not required as findings did not identify a design, labeling or manufacturing non-conformity.The event will be re-evaluated if additional information becomes available.Oscor will continue to monitor this event type and risk.
|